(Q46174098)

English

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Giorgina Specchia

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Carmen Baldazzi

object named as

Carmen Baldazzi

5

0 references

Francesca Palandri

object named as

Francesca Palandri

1

0 references

Nicoletta Testoni

object named as

Nicoletta Testoni

2

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

11

0 references

Gianantonio Rosti

14

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

20 December 2017

Fausto Castagnetti

7

object named as

Fausto Castagnetti

1 reference

Europe PubMed Central

20 December 2017

Giovanni Martinelli

12

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

20 December 2017

Michele Baccarani

13

object named as

Michele Baccarani

1 reference

Europe PubMed Central

20 December 2017

Massimo Breccia

8

object named as

Massimo Breccia

1 reference

Europe PubMed Central

20 December 2017

3

object named as

Simona Luatti

1 reference

Europe PubMed Central

20 December 2017

Giulia Marzocchi

4

object named as

Giulia Marzocchi

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Monica Stacchini

6

object named as

Monica Stacchini

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

10

object named as

Fabrizio Pane

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

publication date

1 January 2009

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Leukemia & Lymphoma

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

50

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

114-118

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

The cytogenetic response as a surrogate marker of survival

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1080%2F10428190802492415

21 January 2018

Identifiers

10.1080/10428190802492415

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19125382

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46174098&oldid=2097433503"